Allergan Inc (AGN)

AGN on New York Consolidated

168.21USD
19 Sep 2014
Price Change (% chg)

$-1.76 (-1.04%)
Prev Close
$169.97
Open
$170.67
Day's High
$171.27
Day's Low
$167.26
Volume
1,925,832
Avg. Vol
1,909,022
52-wk High
$174.49
52-wk Low
$88.34

AGN

Chart for AGN

About

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye,... (more)

Overall

Beta: 0.75
Market Cap (Mil.): $49,989.29
Shares Outstanding (Mil.): 297.18
Dividend: 0.05
Yield (%): 0.12

Financials

  AGN Industry Sector
P/E (TTM): 38.53 32.84 33.70
EPS (TTM): 4.37 -- --
ROI: 14.59 18.11 17.35
ROE: 21.11 18.82 18.21
Search Stocks

Allergan reaches truce with suitors on special shareholder meeting

- Allergan Inc has agreed not to throw up any roadblocks to a special shareholder meeting on Dec. 18, giving Pershing Square Capital Management a chance to attempt its threatened replacement of Allergan board members.

16 Sep 2014

UPDATE 2-Allergan reaches truce with suitors on special shareholder meeting

Sept 16 - Allergan Inc has agreed not to throw up any roadblocks to a special shareholder meeting on Dec. 18, giving Pershing Square Capital Management a chance to attempt its threatened replacement of Allergan board members.

16 Sep 2014

Allergan, suitors agree to hold special shareholder meeting on Dec. 18

Sept 16 - Allergan Inc said it has reached an agreement with suitors Pershing Square Capital Management and Valeant Pharmaceuticals Inc to hold a special shareholder meeting on the originally scheduled date, Dec. 18.

16 Sep 2014

CORRECTED-UPDATE 4-Allergan investors owning 35 pct to demand special meeting

(Corrects first paragraph to show that investors owning more than 35 pct of shares, not more than 35 percent of investors, called for meeting)

12 Sep 2014

Deals of the day- Mergers and acquisitions

(Updates EMC; Adds Akorn, Comcast, Grupos Salinas, Lucchini, Dentsu Aegis, Slovenske Elektrarne, Enel, BauMax, Verizon, Wind, BSkyB, Allergan, Hapag-Lloyd, Douglas, Eastman Chemical and Vodafone)

11 Sep 2014

Allergan investors owning 35 percent to demand special meeting: sources

NEW YORK - Billionaire William Ackman has signed up Allergan investors who combined own at least 35 percent of the company to call a special shareholder meeting, according to people familiar with the matter, giving the hedge fund manager a victory in his fight to acquire the Botox maker.

11 Sep 2014

UPDATE 3-Allergan investors owning 35 pct to demand special meeting -sources

NEW YORK, Sept 11 - Billionaire William Ackman has signed up Allergan investors who combined own at least 35 percent of the company to call a special shareholder meeting, according to people familiar with the matter, giving the hedge fund manager a victory in his fight to acquire the Botox maker.

11 Sep 2014

Allergan investors owning 35 pct to demand special meeting-sources

NEW YORK, Sept 11 - Billionaire William Ackman is close to signing up Allergan investors who combined own at least 35 percent of the Botox maker to call a special shareholder meeting, according to people familiar with the matter, giving the hedge fund manager a victory in his fight to acquire Allergan.

11 Sep 2014

Ackman urges Allergan board to 'wake up' on Valeant talks

BOSTON - After months of staying largely silent on a deal he is trying to broker, billionaire William Ackman on Tuesday criticized Allergan Inc 's board of directors, urging them to "wake up" and at least listen to what potential purchaser Valeant Pharmaceuticals has to offer the Botox maker.

09 Sep 2014

UPDATE 1-Ackman urges Allergan board to 'wake up' on Valeant talks

BOSTON, Sept 9 - After months of staying largely silent on a deal he is trying to broker, billionaire William Ackman on Tuesday criticized Allergan Inc 's board of directors, urging them to "wake up" and at least listen to what potential purchaser Valeant Pharmaceuticals has to offer the Botox maker.

09 Sep 2014

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,600 +17.00
Santen Pharmaceutical Co Ltd (4536.T) ¥5,980 -10.00
Lupin Limited (LUPN.NS) Rs1,400.85 +23.35
Nestle SA (NESN.VX) CHF70.40 +0.05
Johnson & Johnson (JNJ.N) $107.99 +0.64
Pfizer Inc. (PFE.N) $30.40 -0.18
Novartis AG (NOVN.VX) CHF88.30 -0.15
High Tech Pharm Co.,Ltd. (106190.KQ) ₩14,150.00 -50.00
Merck & Co., Inc. (MRK.N) $60.49 +0.18
Roche Holding Ltd. (ROG.VX) CHF283.20 -0.10

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks